U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07305987) titled 'PRO-232 in Patients Subjected to Cataract Surgery' on July 30.
Brief Summary: The main objective of this study is to evaluate the efficacy and safety of the PRO-232 formulation manufactured by Laboratorios Sophia S.A. de C.V. on the ocular surface of postoperative cataract patients versus a concomitant administration of ophthalmic moxifloxacin and dexamethasone.
Study Start Date: Oct. 27
Study Type: INTERVENTIONAL
Condition:
Cataract Extraction
Intervention:
DRUG: Moxifloxacin / Dexamethasone Ophthalmic Solution
Moxifloxacin 0.5% / Dexamethasone phosphate 0.1% Ophthalmic solution
DRUG: Placebo
Same excipients as PRO-232, wi...